Medical/Pharmaceuticals

Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...

2022-11-28 22:59 5122

SeekIn Receives CE-IVD Mark Approval for SeekInCure® Cancer Recurrence Monitoring Kit

First-of-its-kind blood-based pan-cancer recurrence monitoring test SHENZHEN, China, Nov. 28, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for SeekInCure® Cancer Recurrence Moni...

2022-11-28 21:00 4136

DetectedX Introduces ImageDx to Transform Image-Based Education at RSNA

Showcases Momentum with New Customers, New Subscriber Options and the Addition ofProfessor László Tabár to the Executive Team CHICAGO, Nov. 28, 2022 /PRNewswire/ -- Building on the successful U.S. launch at the SBI/ACR Breast Imaging Symposium, DetectedX, the leaders in intelligent interactive ...

2022-11-28 21:00 3945

Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan

NEW TAIPEI CITY, Taiwan, Nov. 28, 2022 /PRNewswire/ -- Medeologix, a Taiwan MedTech CDMO company announces its successful acquisition of three premier medical device manufacturing companies to form an integrated full function service group. The newly formed Medeologix family of companies, with a ...

2022-11-28 21:00 5317

GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)

SHANGHAI and NEW ORLEANS, Nov. 28, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the preliminary safety and efficacy data from the Phase I study of GFH009 monotherapy for treatment ...

2022-11-28 19:00 3409

Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients

* LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent * Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ -- Lyvgen Biopharma, a leading innovative glob...

2022-11-28 07:00 2530

New study on deep learning technology for improving MRI image quality published in European Radiology

SwiftMR™, an AI-powered MRI reconstruction solution from AIRS Medical proved its performance for enhancing the image quality of 3D high-resolution MRI SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- A recent study published in European Radiology

2022-11-25 23:00 13921

Neurophet, to participate in the Radiological Society of North America RSNA 2022

̵ Introducing 4 products at the booth including the main product Neurophet AQUA ̵ Conducting in-depth discussions jointly team members from R&D and cooperation with several global companies SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution comp...

2022-11-25 22:00 12974

Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm

* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...

2022-11-25 21:00 13151

Concord Medical Schedules 2022 Annual Meeting of Shareholders

BEIJING, Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensi...

2022-11-25 19:30 12776

Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System

SUZHOU, China, Nov. 25, 2022 /PRNewswire/ -- inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrentia...

2022-11-25 16:00 3408

Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND

SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycythemia vera was formally approved by the United States Food...

2022-11-24 21:00 5140

AnchorDx Enrolls the First Patient For Its UriFind® Bladder Cancer Assay Clinical Trial in the U.S.

GUANGZHOU, China, Nov. 23, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in...

2022-11-23 22:00 4677

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Nov. 23, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...

2022-11-23 21:00 4924

J INTS BIO, M.D Anderson Cancer Center joint development - oral HSP90 inhibitor 'JIN-001', presentation of preclinical assessment at 2022 SNO Annual Meeting

SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally administered 2nd generation HSP90 (heat shock protein 90) inhibitor, was presented during the 2022 edition of the Society for Neuro-Oncology Conference, h...

2022-11-23 15:18 2465

Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing

NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off inNanjing. The theme of t...

2022-11-23 14:19 2831

Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand

INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an ...

2022-11-22 20:00 3046

IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer

SYDNEY, Nov. 21, 2022 /PRNewswire/ --  Highlights * Clarity's fifth successful Investigational New Drug (IND) application with theUnited States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin * A total of six products with both the diagnostic and t...

2022-11-21 22:04 4467

United Imaging Drives Forward Several Major Innovations in Multiple Imaging Modalities

The company's IPO and 20,000th global installation are followed by new technological innovations, in keeping with its commitments to the U.S. and other markets. HOUSTON, Nov. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment...

2022-11-21 22:00 4075

Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified

* Lunit becomes first software as a medical device (SaMD) company in APAC to become MDR CE and UKCA certified * MDR and UKCA certifications are required for all Europe and UK commercial medical devices with implementation deadlines set to 2024 SEOUL, South Korea, Nov. 21, 2022 /PRNewswire/ --...

2022-11-21 21:00 3673
1 ... 201202203204205206207 ... 262